# Does sodium bicarbonate based extra-cellular buffering support reduce high intensity exercise-induced fatigue and enhance shortterm recovery assessed by selected blood biochemical indices?

AUTHORS: Krzysztof Durkalec-Michalski<sup>1,2</sup>, Joanna Kamińska<sup>3</sup>, Bryan Saunders<sup>4,5</sup>, Andrzej Pokrywka<sup>6</sup>, Igor Łoniewski<sup>7</sup>, Michal Steffl<sup>2</sup>, Tomasz Podgórski<sup>3</sup>

<sup>1</sup> Department of Sports Dietetics, Poznan University of Physical Education, 61-871 Poznan, Poland

- <sup>2</sup> Sport Sciences–Biomedical Department, Faculty of Physical Education and Sport, Charles University, 162 52 Prague, Czech Republic
- <sup>3</sup> Department of Physiology and Biochemistry, Poznan University of Physical Education, 61-871 Poznan, Poland
- <sup>4</sup> Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, Rheumatology
- Division, Faculdade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil
- <sup>5</sup> Institute of Orthopedics and Traumatology, Faculty of Medicine FMUSP, University of São Paulo, Brazil
- <sup>6</sup> Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, 02-097 Warsaw, Poland
- <sup>7</sup> Department of Biochemical Sciences, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland

ABSTRACT: Exercise-induced metabolic processes induce muscle acidification which contributes to a reduction in the ability to perform repeated efforts. Alkalizing agents such as sodium bicarbonate (NaHCO<sub>3</sub>) prevent large blood pH changes, however, there is no evidence on whether regulation of acid-base balance may also support whole body homeostasis monitored through heamatological and biochemical blood markers in a dose-dependent manner. Thirty Cross-Fit-trained participants were studied in a randomized, multi cross-over, placebo (PLA)controlled double-blind manner in which they performed a control session (CTRL, without supplementation), three NaHCO<sub>3</sub> visits (three different doses) and PLA (sodium chloride in an equimolar amount of sodium as NaHCO<sub>3</sub>). Each visit consisted of two 30-s Wingate tests separated by CrossFit-specific benchmarks (Wall Balls and Burpees - both performed for 3 min). Blood samples were collected at rest, immediately post-exercise and after 45 min recovery. Significant differences between visits appeared for blood pH, percentage of lymphocytes and granulocytes, red blood cells count and haemoglobin concentration at post-exercise and 45-min recovery, and for white blood cells count, percentage of monocytes, concentration of magnesium and creatinine at 45-min recovery. Most of the observed differences for heamatological and biochemical markers were significant compared to CTRL, but not different after PLA. NaHCO<sub>3</sub> supplementation compared to PLA did not significantly affect exercise or recovery shifts in studied blood indicators. However, the changes in these markers after NaHCO3 and PLA in relation to CTRL indicate a possible role of sodium.

**CITATION:** Durkalec-Michalski K, Kamińska J, Saunders B et al. Does sodium bicarbonate based extra-cellular buffering support reduce high intensity exercise-induced fatigue and enhance short-term recovery assessed by selected blood biochemical indices? Biol Sport. 2024;41(1):17–27.

Received: 2022-12-27; Reviewed: 2023-02-06; Re-submitted: 2023-02-08; Accepted: 2023-02-12; Published: 2023-05-25.

#### Corresponding author: Krzysztof Durkalec-Michalski Department of Sports Dietetics Poznan University of Physical Education, 61-871 Poznan Poland Tel.: +48 61 835 51 65 e-mail: durkalec-michalski@awf. poznan.pl

#### ORCID:

Krzysztof Durkalec-Michalski 0000-0002-5041-2981

Joanna Kamińska 0000-0002-7907-3143

Bryan Saunders 0000-0003-0995-9077

Andrzej Pokrywka 0000-0003-4217-7560

Igor Łoniewski 0000-0002-5398-4985

Michal Steffl 0000-0001-7297-8145

Tomasz Podgórski 0000-0003-0745-4606

#### Key words:

CrossFit Supplementation Muscle damage Heamatological markers Sodium bicarbonate Biochemical markers

## INTRODUCTION

The high energy request of the organism during intensive efforts and the need for rapid anaerobic ATP resynthesis lead to the release of protons that decrease blood pH, and cause muscle acidification [1]. This occurs predominantly during high-intensity exercises and training programs, such as high-intensity interval training (HIIT) and/or high-intensity functional training (HIFT). It is well known that increased muscle acidification is one of the main suppressors of the ability to perform high-intensity exercise [2]. Moreover, HIIT/HIFT may influence homeostatic disturbances not only directly through the acid-base balance, but also indirectly affecting the various haematological and biochemical markers. However, post-exercise changes in these indices, especially haematological and muscle damage-specific markers, are equivocal.

White blood cell (WBC) count increases immediately after intense exercise [3, 4, 5]. Furthermore, despite an increase in WBC after HIIT and continuous aerobic exercise, WBC elevation is remarkably higher for HIIT than continuous aerobic exercise [6]. In addition, shifts in post-exercise haematological markers are related to an increase in the percentage of lymphocytes (LYM%) [4, 5, 6], monocytes (MON%) [4], and a decrease of granulocytes (GRA%) [6]. However, changes of the aforementioned markers are not always repeatedly recorded [6]. Similarly, ambiguous positions relate to exercise-induced

changes of platelets (PLT), red blood cells (RBC) count and heamoglobin (HGB) concentration [3, 5, 7, 8].

Moreover, in most studies, relating to changes in blood biochemical markers, post-exercise increases in lactate dehydrogenase (LDH) [9], creatine kinase (CK) [3, 8, 9], alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [10] activities or urea [11] and magnesium [7] concentrations have been shown, although changes in these indicators after intense efforts have not always been shown [10].

It is interesting to note that the aforementioned biochemical changes are sensitive to pH reductions induced by high-intensity exercise, which may affect the haematological profile in blood due to the role of haemoglobin as a buffer in the body [12] and increasing the risk of osmotic fragility of erythrocytes [13]. Furthermore, acidosis resulting from chronic kidney disease stimulates the activity of the ubiquitin-proteasome pathway and the formation of glucocorticoids, which contribute to the degradation of muscle proteins, and thus to an increase in blood urea concentration [14]. It would be reasonable to assume that this mechanism may also be reflected in acidosis resulting from highly intensive exercise.

While it is unwise to interfere with training and reduce the intensity of exercise (which may negatively affect adaptation and sports performance), an alternative to support the body's buffering needs is nutritional and/or supplementation support. Alkalizing agents, such as sodium bicarbonate (NaHCO<sub>3</sub>), improve CrossFit-like performance [15] and have significant ergogenic effects [16] through increasing blood buffering capacity [17], which allows greater hydrogen ion (H<sup>+</sup>) binding, H<sup>+</sup>/lactate shuttle from working myocytes, and increases extra-cellular pH [16, 18].

NaHCO<sub>3</sub> intake increases pH, through an elevation of bicarbonate ion (HCO<sub>3</sub><sup>-</sup>) concentration in the blood, which may be beneficial in exercises heavily reliant on anaerobic metabolism [16]. Excessive sodium bicarbonate administration may induce severe alkalaemia, hypernatraemia and hypokalaemia [19]. However, in sport practice commonly supplemented doses ranging from 0.1 to  $0.5 \, g \cdot kg^{-1}_{BM}$  NaHCO<sub>3</sub> [16, 20] do not appear to be a cause for concern. The ideal supplementation method appears to be ingestion in a solution or gelatine capsules at a dose of  $\geq 0.3 \, g \cdot kg^{-1}_{BM}$  NaH-CO<sub>3</sub> 60–180 min before exercise [16, 20, 21]. However, there are also reports that do not confirm this positive influence of NaH-CO<sub>3</sub> [22, 23]. This may be due to the large diversity of the organism's individual response to this agent and supplementation protocols [20, 24], or related to digestive system problems that can appear in some people [18, 25]. Due to lower tolerance, some athletes choose lower doses ( $\sim$ 0.2 g·kg<sup>-1</sup><sub>BM</sub>) and lengthening the time between NaHCO<sub>3</sub> intake and exercise starting ( $\sim$ 180 min), which may also have an ergogenic benefit [16, 20, 26]. On the other hand, Grgic et al. [20] reported the use of higher doses (0.4–0.5 g·kg<sup>-1</sup><sub>BM</sub>) did not provide any additional benefits compared to the dose of 0.3 g·kg<sup>-1</sup><sub>BM</sub> NaHCO<sub>3</sub>. Therefore, despite performance effects, it is crucial to investigate the multidirectional impact of NaHCO<sub>3</sub> on wholebody homeostasis during intense exercise.

It is not known to what extent acute HIIT/HIFT-induced changes in haematological and biochemical indicators are modulated by NaH- $CO_3$  supplementation. Extracellular buffering capacity elevation through NaHCO<sub>3</sub> intake, proportionally to the administered dose, may enhance acid-base balance during efforts and could translate into changes in haematological and blood biochemical markers. The aim of this study was to verify the extent to which NaHCO<sub>3</sub> would affect the acute changes of haematological and blood biochemical markers following intense exercise. We hypothesized that NaH- $CO_3$  would minimize exercise-induced changes in these markers in a dose-dependent manner.

# MATERIALS AND METHODS

## Participants

Thirty-four Cross-Fit-trained participants were initially enrolled in the study. Due to personal and professional reasons (business trips) 4 subjects (3 males (M)/1 female (F)) dropped-out of the study. Thirty athletes (16M/14F) completed the whole study protocol and were included in the analyses. The participants were regularly training HIFT in CrossFit-affiliated clubs in Poznań (*"Hangar"* and *"Staj-nia CrossFit"*) and Szczecin (*"Papaj CrossFit"*) in Poland (Table 1).

The inclusion criteria were: a valid and up-to-date medical certificate that confirmed the athlete's ability to practice sports, good general health, at least 4 years of training experience and participation in a minimum of four CrossFit workout sessions a week. The exclusion criteria were: current injury, health-related contraindication,

Characteristics	Mean ± SD	95% CI
Age [years]	$30.6 \pm 4.3$	(29.0–32.2)
Body mass [kg]	$73.8 \pm 12.1$	(69.3–78.3)
Fat-free mass [kg]	$59.8 \pm 11.5$	(55.4–64.1)
Fat mass [%]	$19.1 \pm 5.5$	(17.1–21.2)
Body height [cm]	$175 \pm 9$	(172–178)

**TABLE 1.** Somatic and physiological characteristics of participants training Cross-Fit<sup>®</sup> (n = 30).

SD - standard deviation; CI - confidence interval

declared general feeling of being unwell and unwillingness to follow the study protocol.

The local institutional review board reviewed and approved the study protocol (Bioethics Committee at Poznan University of Medical Sciences, reference number: 1000/18 of 11 October 2018). The study protocol was also registered at *ClinicalTrials.Gov* (NCT03810404). All procedures were conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and written informed consent was obtained from all participants before their participation in the study began.

The required sample size was calculated a priori using a computer statistical package Statistica 13.3 (StatSoft, Inc., Tulsa, OK, USA) based on results of other studies [27, 28]. It was estimated that a sample size of 28 would be suitable for detecting a difference between blood pH measurements to obtain a power of approximately 90% ( $\alpha = 0.05$ ) in analysis of variance (ANOVA) with repeated measurements (RM) within factors.

# Study design

Supplementation of various NaHCO<sub>3</sub> doses was evaluated in a randomized, multi cross-over, placebo (*PLA*)-controlled double-blind trial. The protocol of the study consisted of five visits ( $T_1-T_5$ ) for each participant (Figure 1). In T1, a control (*CTRL*) phase was carried out where all tests without supplementation or *PLA* administration were performed. During subsequent visits ( $T_2-T_5$ ), studies were conducted after three different doses of NaHCO<sub>3</sub> and *PLA* intake depending on a randomization-based supplementation order.

All participants had substantial experience in performing the exercise procedures. They were also obligated to eat a standardized meal (containing 2 g of carbohydrates per kilogram of body mass (BM), 30 g of protein and at least 7 ml of water per kilogram of BM) two hours before each visit. Diet of the participants was monitored by an experienced dietician who ensured that athletes met all recommended criteria in terms of nutritional standards [29]. Furthermore, participants did not follow any specific nutritional strategy and did not change any nutritional aspects during the study protocol.

The study visits  $(T_1-T_5)$  were separated by at least 7-days of washout.

# Supplementation

The NaHCO<sub>3</sub> doses were provided relative to fat-free mass (FFM). The dose of supplemented NaHCO<sub>3</sub> was considered as *LOW* (0.15 g·kg<sup>-1</sup><sub>FFM</sub> of NaHCO<sub>3</sub>), *MEDIUM* (0.25 g·kg<sup>-1</sup><sub>FFM</sub> of NaHCO<sub>3</sub>, *MED*) and *HIGH* (0.35 g·kg<sup>-1</sup><sub>FFM</sub> of NaHCO<sub>3</sub>). NaHCO<sub>3</sub> in the form of powder was used (Alkala N, Sanum-Kehlbeck GmbH & Co. KG, Germany; containing 89.1% of NaHCO<sub>3</sub>, 9.9% of potassium bicarbonate, and 1.0% of sodium citrate). *PLA* preparation was provided in a similar powder form and contained sodium chloride in an equimolar amount of sodium as *MED* NaHCO<sub>3</sub>. All preparations were dissolved in approximately 750 mL of fluid (600 mL of water and 150 mL of orange juice). Juice was provided as a source of CHO to alleviate GI

symptoms [18, 25, 30] and improve the taste of the preparations. Athletes were obligated to drink the preparations 2 h before the exercise tests within 5 min and were supervised by a member of the research team.

#### Anthropometric measurements

Anthropometric measurements were performed according to recommendations as described previously [31]. Body mass and height were measured using a professional medical scale (WPT 60/150 OW, RADWAG, Radom, Poland). Body composition and total body water were assessed via bioelectric impedance, using Bodystat 1500MDD (Bodystat Inc., Douglas, UK).

#### Exercise tests

The exercise battery started 2 h after NaHCO<sub>3</sub>/*PLA* intake (or fluid intake at *CTRL* –  $T_1$  visit). Each visit consisted of two classic 30-s Wingate tests (WAnT\_1 and WAnT\_2) separated by CrossFit-specific benchmarks: a) Wall Balls (performed for 3 min) and (after a 30 s transition break) b) Burpees (performed for 3 min). The Wall Balls task started exactly 5 min after the completion of WAnT\_1, and WAnT\_2 started 5 min after the completion of the Burpees task. The actual high-intensity active effort lasted a total of 7 min.

The exercise tests were always preceded by a standardized 10 min warm-up as previously described [31]. WAnTs were performed on a Monark 894E cycloergometer (Varberg, Sweden) and external loading was adjusted individually at 7.5% body weight [31]. During the CrossFit-specific benchmarks, the participants were instructed to perform as many repetitions of each exercise as they could during 3 min. Repetitions were accounted for, only if the participant completed a full range of motion required for each exercise. The only difference in CrossFit-specific benchmarks between female and male participants was the weight of the medicine ball during wall balls (6 and 9 kg for females and males) [32]. Participants were verbally encouraged to exert maximum effort throughout the exercise tests.

#### Biochemical analyses

Capillary blood was obtained from the fingertip, at rest before supplementation (2 h before exercise), 3 min after (post-exercise) and 45 min (recovery) after exercise. Blood was collected according to the applicable and standardized procedures, from the finger of the nondominant hand using Medlance Red lancet-spike (HTL-Zone, Berlin, Germany) with a 1.5 mm blade and 2.0 mm penetration depth. A heparinized capillary sample (65  $\mu$ l; Radiometer, Copenhagen, Denmark) was taken to determine pH using a blood gas analyzer (ABL90 FLEX, Radiometer, Copenhagen, Denmark). Additionally, 300  $\mu$ l of capillary blood was collected in a Microvette CB 300 tube (Sarstedt, Nümbrect, Germany) containing EDTA dipotassium salt as an anticoagulant for WBC and their individual fractions (LYM%, MON%, GRA%), RBC, HGB, haematocrit (HCT) and PLT determination on a haematology analyzer (Mythic18, Orphèe, Geneva, Switzerland);



FIG. 1. A flow chart of the study design.

CTRL – control visit, without supplementation or placebo treatment; HIGH – visit with high NaHCO<sub>3</sub> dose (0.35 g  $\cdot$  kg<sup>-1</sup><sub>Fat-Free Mass</sub>); LOW – visit with low NaHCO<sub>3</sub> dose (0.15 g  $\cdot$  kg<sup>-1</sup><sub>Fat-Free Mass</sub>); MED – visit with medium NaHCO<sub>3</sub> dose (0.25 g  $\cdot$  kg<sup>-1</sup><sub>Fat-Free Mass</sub>); NaHCO<sub>3</sub> – sodium bicarbonate; PLA – placebo; T<sub>0</sub>–T<sub>5</sub> – numbers of study visits; WAnT – 30-s Wingate Anaerobic Test.



**FIG. 2.** Resting (A), post-exercise (B) and recovery (C) pH values in the five phases (I-V). CI – confidence interval; CTRL – control visit, without supplementation or placebo treatment; HIGH – visit with high NaHCO<sub>3</sub> dose (0.35  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); LOW – visit with low NaHCO<sub>3</sub> dose (0.15  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); MED – visit with medium NaHCO<sub>3</sub> dose (0.25  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); NaHCO<sub>3</sub> – sodium bicarbonate; PLA – placebo.

<sup>1,II,III,IV,V</sup>The values of the phase, which number is in the superscript, are significantly lower than the values at which they are presented; <sup>A,B,C</sup>The values of the moment, which letter is in the superscript, are significantly lower than the values at which they are presented.

and after plasma separation concentration of urea and creatinine, and ALT, AST, CK, and LDH activities on the Accent 220S automatic biochemical analyser (Cormay, Łomianki, Poland). Another 300  $\mu$ l of capillary blood was collected in a Microvette CB 300 Z tube (Sarstedt, Nümbrect, Germany) with a clotting activator, in which the serum concentration of magnesium was marked also on the Accent 220S automatic biochemical analyzer.

Additionally, to avoid misinterpretation of blood parameter results due to different hydration status of participants on different visits, haematology indicators were related to the number of cellular components (WBC, RBC, HGB, PLT) and all biochemical parameters were converted using the haematocrit correction formula [33, 34].

## Statistical Analysis

Data are presented as the mean and standard deviation ( $\pm$  SD) and the 95% confidence interval for the mean (95% CI). The studied variables were checked for normal distribution using the Shapiro-Wilk test. For the comparison of the results between the five visits ( $T_1-T_5$ ) and collection moment (rest, post-exercise and recovery), repeated measures ANOVA were performed for normally distributed data. For data that was not normally distributed, the Friedman ANOVA test was selected. Post-hoc (Tukey HSD test for parametric statistics and post hoc for Friedman for nonparametric statistics) analyses were then conducted for statistically significant data. The level of significance was set at p < 0.05. Statistical analysis was performed using a computer statistical package STATISTICA 13.3 (StatSoft, Inc., Tulsa, OK, USA).

#### **RESULTS**

The resting (rest) values of all haematological, biochemical and blood gas measures did not differ significantly from one another across  $T_1-T_5$ .

## Blood pH value

All blood pH results are presented in Figure 2.

An exercise-induced decrease in pH (p < 0.001) was shown between post-exercise vs. resting values for each visit (*NaHCO*<sub>3</sub>'s, *CTRL*, *PLA*). However, in the recovery period, pH returned or even significantly exceeded (in *MED* and *HIGH*) the resting values after NaHCO<sub>3</sub>.

**TABLE 2.** Summary of the level of blood haematological parameters resting, post-exercise and recovery in the five visits of the study (n = 30).

Indicator	Measurement	STUDY VISITS [Mean ± SD (95% CI)]							
Indicator	time	CTRL (I)	LOW (II)	MED (III)	HIGH (IV)	PLA (V)	<i>p</i> -value		
	Decting (A)	$7.7 \pm 1.6$	$7.6 \pm 1.9$	$7.6 \pm 1.7$	$7.7 \pm 1.7$	$7.4 \pm 1.9$	0.206		
e blood [10 <sup>9</sup> /L]	Resting (A)	(7.1–8.3)	(6.9–8.3)	(7.0-8.2)	(7.0-8.3)	(6.7-8.1)	0.200		
	Deat avaraiaa (D)	$13.2 \pm 3.9^{A,C}$	$13.1 \pm 2.5^{A,C}$	$13.1 \pm 2.7^{A,C}$	$13.3 \pm 2.8^{A,C}$	$13.2 \pm 2.9^{A,C}$	0 746		
	Post-exercise (B)	(11.8–14.6)	(12.2–14.1)	(12.1 - 14.1)	(12.2–14.3)	(12.1–14.3)	0.746		
/hit ells		$9.6 \pm 2.8^{II,III,IV,V,A}$	$8.1 \pm 2.3$	$8.4 \pm 2.6$	$8.0 \pm 2.2$	$8.3 \pm 2.6^{A}$	< 0.001		
≤ ७	Recovery (C)	(8.6–10.7)	(7.2–9.0)	(7.4–9.4)	(7.1–8.8)	(7.4–9.3)	< 0.001		
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			
	Decting (A)	$35.1 \pm 7.0^{\circ}$	$35.1 \pm 6.7^{\circ}$	$35.0 \pm 7.4^{\circ}$	$34.3 \pm 6.6^{\circ}$	35.7 ± 7.1 <sup>°</sup>	0.833		
%]	Resting (A)	(32.4–37.7)	(32.6–37.6)	(32.2–37.7)	(31.8–36.7)	(33.0–38.3)			
tes	Deat avaraiaa (D)	$44.1 \pm 8.2^{A,C}$	$46.4 \pm 7.5^{A,C}$	$47.1 \pm 6.4^{A,C}$	$44.9 \pm 8.7^{A,C}$	$47.0 \pm 9.8^{A,C}$	0.048*		
)cy	POST-exercise (D)	(41.0-47.2)	(43.6–49.2)	(44.7–49.5)	(41.7–48.1)	(43.3–50.6)			
phq	Boowery (C)	$23.0 \pm 7.7$	$28.3 \pm 8.2^{1}$	$28.8 \pm 9.2^{1}$	$28.6 \pm 9.4^{1}$	$28.3 \pm 10.2^{1}$	0.004		
Т.	Recovery (C)	(20.2–25.9)	(25.3–31.4)	(25.4–32.3)	(25.1–32.1)	(24.5–32.1)			
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			
	Posting (A)	$6.7 \pm 1.7^{\circ}$	$6.8 \pm 1.9$	$7.2 \pm 1.8$	$7.1 \pm 2.3$	$6.8 \pm 2.3$	0.467		
[%]	Resting (A)	(6.1–7.4)	(6.1–7.5)	(6.5–7.9)	(6.2–7.9)	(6.0–7.7)			
] S	Deat avaraiaa (D)	$7.2 \pm 1.8^{\circ}$	$7.5 \pm 1.6^{A,C}$	$7.8 \pm 1.7$	$7.5 \pm 1.6$	$7.4 \pm 1.3^{A,C}$	0.200		
cyte	FUST-EXERCISE (D)	(6.5–7.9)	(6.9-8.1)	(7.1-8.4)	(6.9-8.1)	(6.9–7.9)			
DOUG	Bacayony (C)	$6.1 \pm 2.2$	$6.7 \pm 1.7$	$7.5 \pm 2.6^{1}$	$7.4 \pm 2.9$	$6.7 \pm 1.9$	0.012		
MG	Recovery (C)	(5.3–6.9)	(6.1–7.3)	(6.5-8.4)	(6.3–8.5)	(6.0–7.4)			
	<i>p</i> -Value	< 0.001	< 0.001	0.209	0.121	0.001			
	Desting (A)	$58.2 \pm 7.7^{B}$	$58.1 \pm 7.1^{B}$	$57.8 \pm 7.6^{B}$	$58.7 \pm 6.9^{B}$	$57.5 \pm 7.9^{B}$	0.714		
%]	Nesting (A)	(55.4–61.1)	(55.4–60.8)	(55.0–60.7)	(56.1–61.2)	(54.6–60.5)			
tes	Deat averaina (P)	$48.7 \pm 9.0$	$46.1 \pm 7.8$	$45.2 \pm 6.8$	$47.6 \pm 9.2$	$45.6 \pm 10.4$	0.037*		
JCY	FUST-EXERCISE (D)	(45.3–52.0)	(43.2–49.0)	(42.6–47.7)	(44.1–51.0)	(41.7–49.5)			
nulo	Recovery (C)	$70.9 \pm 8.9^{\text{II},\text{III},\text{IV},\text{V},\text{A},\text{B}}$	$65.0 \pm 8.4^{A,B}$	$63.7 \pm 9.9^{A,B}$	$64.0 \pm 10.1^{A,B}$	$65.0 \pm 10.5^{A,B}$	< 0.001		
araı	Recovery (C)	(67.6–74.2)	(61.8–68.1)	(60.0–67.4)	(60.2–67.7)	(61.1–68.9)			
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			
	Resting (A)	$5.96 \pm 0.59$ <sup>B</sup>	$5.94 \pm 0.59^{B}$	$5.92 \pm 0.55^{B,C}$	$5.91 \pm 0.53^{B,C}$	$5.90 \pm 0.55^{B}$	0 1 1 0		
- <u>-</u>		(5.74–6.19)	(5.72–6.16)	(5.71–6.12)	(5.71–6.10)	(5.70-6.11)	0.119		
000 0 <sup>12</sup> /	Post-evercise (B)	$5.88 \pm 0.59^{III}$	$5.86 \pm 0.60$	$5.81 \pm 0.54$	$5.82 \pm 0.53$	$5.83 \pm 0.55$	0 033		
ld bl [1(		(5.66–6.10)	(5.63–6.08)	(5.61–6.01)	(5.62–6.02)	(5.62–6.03)	0.000		
Rec	Recovery (C)	$5.96 \pm 0.60^{III,IV,V,B}$	$5.94 \pm 0.59^{B}$	$5.88 \pm 0.53^{B}$	$5.88 \pm 0.52^{B}$	$5.89 \pm 0.56^{B}$	0.007		
S		(5.74–6.18)	(5.72–6.16)	(5.68–6.08)	(5.69–6.08)	$(5.68 \pm 6.10)$	0.007		
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			
	Resting (A)	$10.84 \pm 0.40^{B,C}$	$10.63 \pm 0.48^{B,C}$	$10.75 \pm 0.45^{B,C}$	$10.75 \pm 0.48^{B,C}$	$10.63 \pm 0.46^{B,C}$	0.076		
. <u> </u>		(10.69–10.98)	(10.45–10.81)	(10.58–10.91)	(10.57–10.94)	(10.45–10.80)	0.070		
glot  /L]	Post-exercise (B)	$10.56 \pm 0.47^{11,V}$	$10.29 \pm 0.54$	$10.35 \pm 0.51$	$10.43 \pm 0.62$	$10.35 \pm 0.52$	0 004		
30u Du		(10.38–10.74)	(10.09–10.49)	(10.16–10.54)	(10.20–10.66)	(10.16–10.54)	0.004		
aen [mi	Recovery (C)	$10.71 \pm 0.37^{II,B}$	$10.46 \pm 0.55^{B}$	$10.51 \pm 0.50^{B}$	$10.56 \pm 0.60^{B}$	$10.47 \pm 0.53^{B}$	0.015		
Т		(10.57–10.84)	(10.26–10.67)	(10.32–10.69)	(10.33–10.78)	(10.27–10.66)	0.010		
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			
_	Resting (A)	$269 \pm 95$	$280 \pm 88$	$273 \pm 89$	$272 \pm 78$	$279 \pm 97$	0.081		
J/ <sub>6</sub> (		(234–305)	(247–313)	(240–306)	(243–301)	(242–315)	0.001		
[10	Post-exercise (B)	$302 \pm 114$	$319 \pm 113^{A,C}$	$308 \pm 90^{A,C}$	$302 \pm 93^{A,C}$	$307 \pm 107^{A}$	0.368		
sts		(259–344)	(277–361)	(275–342)	$(268 \pm 337)$	(267–347)	0.000		
tele	Recovery (C)	$264 \pm 97$	$282 \pm 94$	$288 \pm 86$	$267 \pm 82$	$288 \pm 92$	0.061		
Pla		(228–300)	(247–317)	(256–320)	(237–298)	(254–322)	0.001		
	<i>p</i> -Value	0.131	0.001	< 0.001	0.002	0.001			

CI – confidence interval; CTRL – control visit, without supplementation or placebo treatment; HIGH – visit with high NaHCO<sub>3</sub> dose (0.35  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); LOW – visit with low NaHCO<sub>3</sub> dose (0.15  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); MED – visit with medium NaHCO<sub>3</sub> dose (0.25  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); NaHCO<sub>3</sub> – sodium bicarbonate; PLA – placebo; SD – standard deviation

<sup>I,II,III,III,IV,V</sup>The values of the phase, which number is in the superscript, are significantly lower than the values at which they are presented <sup>A,B,C</sup>The values of the moment, which letter is in the superscript, are significantly lower than the values at which they are presented \*The post-hoc test did not show any significant difference between the terms

TABLE 3.	Summary	of the	level c	f blood	biochemical	parameters	resting,	post-exercise	and	recovery	in tł	ne five	visits	of the	e study
(n = 30).															

Indicator	Moosurement time	STUDY VISITS [Mean ± SD (95% CI)]						
muicator		CTRL (I)	LOW (II)	MED (III)	HIGH (IV)	PLA (V)	p-value	
10//L]	Posting $(\Lambda)$	$7.2\pm2.0^{B}$	$7.3 \pm 2.1^{\text{B,C}}$	$7.2\pm2.0^{B}$	$7.0 \pm 1.8^{B}$	$7.2\pm1.9^{\text{B}}$	0.055	
	Resting (A)	(6.5–8.0)	(6.5–8.0)	(6.4–7.9)	(6.4–7.7)	(6.5–7.9)	0.955	
	Post avarsisa (P)	$7.0 \pm 1.9$	$6.6 \pm 1.7$	$6.4 \pm 1.7$	$6.6 \pm 1.8$	$6.6 \pm 1.6$	0.455	
[mn		(6.3–7.7)	(6.0–7.3)	(5.8–7.0)	(5.9–7.2)	(6.0–7.2)	0.455	
rea	Pacovary (C)	$7.3 \pm 1.9^{B}$	$7.0 \pm 1.9^{B}$	$6.8 \pm 1.8^{B}$	$7.0 \pm 1.9^{B}$	$7.1 \pm 1.8^{\text{B}}$	0.621	
		(6.6–8.0)	(6.3–7.7)	(6.2–7.5)	(6.3–7.7)	(6.4–7.7)	0.021	
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001		
-	Pecting (A)	$1.01 \pm 0.14$	$0.97 \pm 0.13$	$1.01 \pm 0.16$	$1.01 \pm 0.15$	$0.99 \pm 0.11$	0.455	
J/lor		(0.96–1.07)	(0.92–1.02)	(0.95–1.07)	(0.96–1.07)	(0.95–1.03)	0.400	
	Post-avarcisa (B)	$1.04 \pm 0.14$	$1.00 \pm 0.12$	$1.01 \pm 0.13$	$0.99 \pm 0.14$	$1.00 \pm 0.12$	0 178	
Ę	FUSI-EXERCISE (D)	(0.98–1.09)	(0.95–1.05)	(0.96–1.06)	(0.94–1.04)	(0.95–1.04)	0.170	
lesiu	Pacovary (C)	$1.15\pm0.19^{\text{IV,A,B}}$	$1.09\pm0.14^{\text{A},\text{B}}$	$1.11\pm0.16^{\rm A,B}$	$1.08\pm0.16^{\text{A},\text{B}}$	$1.09\pm0.14^{\text{A},\text{B}}$	0.034	
Magr	Recovery (C)	(1.08–1.22)	(1.03–1.14)	(1.06–1.17)	(1.02–1.14)	(1.04–1.15)	0.034	
~	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	0.005	< 0.001		
	Pecting (A)	$32.4 \pm 10.4$	$32.8 \pm 13.6$	$31.4 \pm 9.5$	$33.2 \pm 13.8$	$31.8 \pm 10.4$	0 865	
[U/		(28.5–36.3)	(27.7–37.9)	(27.8–34.9)	(28.1–38.4)	(27.9–35.7)	0.005	
ne rase	Post-avarcisa (B)	$34.6\pm10.6^{\rm A}$	$35.2 \pm 14.7^{A,C}$	$32.5\pm9.6^{\text{A}}$	$35.9 \pm 14.3^{A}$	$34.5 \pm 11.3^{A}$	0.610	
Alanir otransfei		(30.7–38.6)	(29.7–40.7)	(29.0–36.1)	(30.6–41.3)	(30.3–38.7)	0.010	
	Recovery (C)	$34.1 \pm 10.2^{\text{A}}$	$34.2 \pm 13.5^{A}$	$32.7\pm9.7^{A}$	$35.3 \pm 14.3^{A}$	$33.2 \pm 10.6^{A}$	0 272	
min		(30.3–37.9)	(29.1–39.2)	(29.0–36.3)	(30.0–40.7)	(29.2–37.1)	0.272	
a	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001		
		$37.1 \pm 11.2$	$34.9 \pm 9.8$	$33.9 \pm 7.1$	$34.3 \pm 10.5$	$33.6 \pm 7.4$	0 378	
	Resting (A)						0.370	
[U/I	Resting (A)	(32.9–41.3)	(31.2–38.5)	(31.3–36.6)	(30.4–38.2)	(30.8–36.3)	01070	
ate rase [U/I	Resting (A)	(32.9–41.3) 39.6 ± 12.5 <sup>A</sup>	(31.2–38.5) 36.6 ± 10.9 <sup>A</sup>	(31.3-36.6) $35.2 \pm 7.3^{A}$	(30.4–38.2) 36.0±11.1 <sup>A</sup>	(30.8–36.3) 35.7 ± 9.2 <sup>A</sup>	0.3/18	
partate nsferase [U/L	Post-exercise (B)	(32.9–41.3) 39.6±12.5 <sup>A</sup> (34.9–44.3)	(31.2–38.5) 36.6±10.9 <sup>A</sup> (32.6–40.7)	(31.3–36.6) 35.2 ± 7.3 <sup>A</sup> (32.5–38.0)	(30.4–38.2) 36.0±11.1 <sup>A</sup> (31.9–40.1)	(30.8-36.3) $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$	0.348	
Aspartate otransferase [U/I	Post-exercise (B)	(32.9-41.3) $39.6 \pm 12.5^{A}$ (34.9-44.3) $38.9 \pm 12.7^{A}$	(31.2-38.5) $36.6 \pm 10.9^{A}$ (32.6-40.7) $36.1 \pm 10.8$	(31.3-36.6) $35.2 \pm 7.3^{A}$ (32.5-38.0) $36.0 \pm 10.3$	(30.4-38.2) $36.0 \pm 11.1^{A}$ (31.9-40.1) $36.4 \pm 11.7^{A}$	(30.8-36.3) $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$	0.348	
Aspartate minotransferase [U/I	Resting (A) Post-exercise (B) Recovery (C)	(32.9-41.3) $39.6 \pm 12.5^{A}$ (34.9-44.3) $38.9 \pm 12.7^{A}$ (34.1-43.6)	(31.2-38.5) $36.6 \pm 10.9^{A}$ (32.6-40.7) $36.1 \pm 10.8$ (32.1-40.1)	(31.3-36.6) $35.2 \pm 7.3^{A}$ (32.5-38.0) $36.0 \pm 10.3$ (32.2-39.8)	(30.4-38.2) $36.0 \pm 11.1^{A}$ (31.9-40.1) $36.4 \pm 11.7^{A}$ (32.0-40.8)	(30.8-36.3) $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ (32.4-38.2)	0.348	
Aspartate aminotransferase [U/L	Resting (A) Post-exercise (B) Recovery (C) p-Value	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ <b>0.006</b>	(31.3-36.6) $35.2 \pm 7.3^{A}$ (32.5-38.0) $36.0 \pm 10.3$ (32.2-39.8) <b>0.014</b>	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$	(30.8-36.3) $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ (32.4-38.2) <b>0.026</b>	0.348	
] Aspartate [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ <b>0.006</b> $346.3 \pm 259.4$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$	0.348	
[U/L] Aspartate aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ <b>0.006</b> $346.3 \pm 259.4$ $(249.5-443.2)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$ $(261.3-514.6)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$	0.348 0.218 0.615	
ase [U/L] Aspartate [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$	0.348 0.218 0.615	
kinase [U/L] aminotransferase [U/L	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ <b>0.006</b> $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ 0.014 $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$	0.348 0.218 0.615 0.371	
tine kinase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$	0.348 0.218 0.615 0.371	
Creatine kinase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$	0.348 0.218 0.615 0.371 0.471	
Creatine kinase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$	0.348 0.218 0.615 0.371 0.471	
] Creatine kinase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value Recovery (C) P-Value	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$ $407 \pm 80$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$ $420 \pm 79$	0.348 0.218 0.615 0.371 0.471	
[U/L] Creatine kinase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$ $(389-445)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$ $407 \pm 80$ $(377-436)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$ $(394-431)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$ $(378-421)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$ $420 \pm 79$ $(391-450)$	0.348 0.218 0.615 0.371 0.471 0.731	
ite Aspartate ase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Resting (A)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$ $(389-445)$ $456 \pm 81^{A}$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$ $407 \pm 80$ $(377-436)$ $450 \pm 91^{A}$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ <b>0.014</b> $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$ $(394-431)$ $452 \pm 51^{A,C}$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$ $(378-421)$ $429 \pm 64^{A}$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$ $420 \pm 79$ $(391-450)$ $463 \pm 95^{A}$	0.348 0.218 0.615 0.371 0.471 0.731 0.195	
actate Creatine kinase [U/L] Aspartate aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) <i>p</i> -Value Resting (A) Post-exercise (B) Recovery (C) <i>p</i> -Value Resting (A) Post-exercise (B)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$ $(389-445)$ $456 \pm 81^{A}$ $(426-486)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$ $407 \pm 80$ $(377-436)$ $450 \pm 91^{A}$ $(417-484)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$ $(394-431)$ $452 \pm 51^{A,C}$ $(433-471)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$ $(378-421)$ $429 \pm 64^{A}$ $(405-453)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$ $420 \pm 79$ $(391-450)$ $463 \pm 95^{A}$ $(427-498)$	0.348 0.218 0.615 0.371 0.471 0.731 0.195	
Lactate Aspartate Aspartate aminotransferase [U/L] Aspartate U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$ $(389-445)$ $456 \pm 81^{A}$ $(426-486)$ $442 \pm 69$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $< 0.001$ $407 \pm 80$ $(377-436)$ $450 \pm 91^{A}$ $(417-484)$ $425 \pm 82$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$ $(394-431)$ $452 \pm 51^{A,C}$ $(433-471)$ $446-122$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$ $(378-421)$ $429 \pm 64^{A}$ $(405-453)$ $420 \pm 70^{A}$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ <b>&lt; 0.001</b> $420 \pm 79$ $(391-450)$ $463 \pm 95^{A}$ $(427-498)$ $440 \pm 80$	0.348 0.218 0.615 0.371 0.471 0.731 0.195 0.306	
Lactate Aspartate dehydrogenase [U/L] aminotransferase [U/L]	Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) P-Value Resting (A) Post-exercise (B) Recovery (C) Recovery (C)	$(32.9-41.3)$ $39.6 \pm 12.5^{A}$ $(34.9-44.3)$ $38.9 \pm 12.7^{A}$ $(34.1-43.6)$ $< 0.001$ $409.3 \pm 360.6$ $(274.7-543.9)$ $462.9 \pm 414.6^{A}$ $(308.1-617.8)$ $472.3 \pm 441.2^{A}$ $(307.6-637.1)$ $< 0.001$ $417 \pm 75$ $(389-445)$ $456 \pm 81^{A}$ $(426-486)$ $442 \pm 69$ $(416-468)$	$(31.2-38.5)$ $36.6 \pm 10.9^{A}$ $(32.6-40.7)$ $36.1 \pm 10.8$ $(32.1-40.1)$ $0.006$ $346.3 \pm 259.4$ $(249.5-443.2)$ $389.5 \pm 281.7^{A}$ $(284.3-494.7)$ $392.3 \pm 282.0^{A}$ $(287.0-497.6)$ $2 < 0.001$ $407 \pm 80$ $(377-436)$ $450 \pm 91^{A}$ $(417-484)$ $425 \pm 82$ $(395-456)$	$(31.3-36.6)$ $35.2 \pm 7.3^{A}$ $(32.5-38.0)$ $36.0 \pm 10.3$ $(32.2-39.8)$ $0.014$ $388.0 \pm 339.2$ $(261.3-514.6)$ $427.6 \pm 369.5^{A}$ $(289.6-565.6)$ $441.9 \pm 379.1^{A}$ $(300.4-583.5)$ $< 0.001$ $412 \pm 50$ $(394-431)$ $452 \pm 51^{A,C}$ $(433-471)$ $446-122$ $(401-492)$	$(30.4-38.2)$ $36.0 \pm 11.1^{A}$ $(31.9-40.1)$ $36.4 \pm 11.7^{A}$ $(32.0-40.8)$ $< 0.001$ $361.7 \pm 255.4$ $(266.4-457.1)$ $404.1 \pm 282.2^{A}$ $(298.7-509.5)$ $405.8 \pm 278.3^{A}$ $(301.8-509.7)$ $< 0.001$ $400 \pm 57$ $(378-421)$ $429 \pm 64^{A}$ $(405-453)$ $420 \pm 70^{A}$ $(394-446)$	$(30.8-36.3)$ $35.7 \pm 9.2^{A}$ $(32.3 \pm 39.1)$ $35.3 \pm 7.8$ $(32.4-38.2)$ <b>0.026</b> $324.2 \pm 238.7$ $(235.0-413.3)$ $372.3 \pm 258.9^{A}$ $(275.6-469.0)$ $374.8 \pm 257.3^{A}$ $(278.7-470.9)$ $< 0.001$ $420 \pm 79$ $(391-450)$ $463 \pm 95^{A}$ $(427-498)$ $440 \pm 80$ $(410-470)$	0.348 0.218 0.615 0.371 0.471 0.731 0.195 0.306	

#### TABLE 3. Continue.

Indicator	Maasuramant time	STUDY VISITS [Mean $\pm$ SD (95% CI)]							
muicator		CTRL (I)	LOW (II)	MED (III)	HIGH (IV)	PLA (V)	p-value		
	$Decting(\Lambda)$	$98.1 \pm 16.4$	$98.8 \pm 13.5$	$100.0 \pm 13.0$	$98.2 \pm 15.2$	$99.9 \pm 13.3$	0.251		
I/L]	Resting (A)	(92.0–104.2)	(93.7–103.8)	(95.2–104.9)	(92.5–103.9)	(95.0–104.9)	0.551		
Post-ex Post-ex Destinine Ceatinine Reco		$112.1\pm20.7^{\text{A,C}}$	$111.2 \pm 15.9^{\text{A}}$	$109.5\pm14.8^{\text{A}}$	$109.0\pm15.9^{\text{A}}$	$110.5\pm19.0^{\rm A}$	0 5 2 9		
	Post-exercise (B)	(104.3–119.8)	(105.3–117.2)	(104.0–115.0)	(103.1–115.0)	(103.4–117.6)	0.556		
		$107.8\pm16.7^{\text{A}}$	$112.7\pm14.5^{\text{I},\text{A}}$	$111.9\pm15.5^{\rm A}$	$110.7\pm17.6^{\rm A}$	$112.9\pm18.9^{\text{I},\text{A}}$	0.003		
	Recovery (C)	(101.5–114.0)	(107.3–118.1)	(106.2–117.7)	(104.1–117.2)	(105.8–120.0)	0.003		
	<i>p</i> -Value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001			

CI – confidence interval; CTRL – control visit, without supplementation or placebo treatment; HIGH – visit with high NaHCO<sub>3</sub> dose (0.35  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); *LOW* – visit with low NaHCO<sub>3</sub> dose (0.15  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); MED – visit with medium NaHCO<sub>3</sub> dose (0.25  $g \cdot kg^{-1}_{Fat-Free Mass}$ ); NaHCO<sub>3</sub> – sodium bicarbonate; PLA – placebo; SD – standard deviation

<sup>1,II,III,IV,V</sup>The values of the phase, which number is in the superscript, are significantly lower than the values at which they are presented <sup>A,B,C</sup>The values of the moment, which letter is in the superscript, are significantly lower than the values at which they are presented

Differences were also visible after exercise (p < 0.001) between all NaHCO<sub>3</sub> doses and *PLA*. Additionally, post-exercise and recovery blood pH was greater *HIGH* in comparison to the other visits. Furthermore, at recovery, pH was higher in *LOW* and *MED* than *CTRL* and *PLA* (p < 0.001).

#### Blood Haematological Markers

#### All haematological results are presented in Table 2.

There were differences at recovery between visits for almost all haemotological measures (out of PLT count). For RBC count and HGB concentration, these differences were also apparent at post-exercise. WBC count (p < 0.001) and GRA% (p < 0.001) were higher in CTRL than all other study visits. Significant differences were shown for percentage of LYM (p = 0.004). MON% was higher only for *MED* vs. CTRL (p = 0.012). In the case of RBC count at post-exercise, CTRL was higher than MED (p = 0.033) and at recovery, CTRL was higher than MED, HIGH and PLA (p = 0.007). HGB concentration postexercise was significantly higher in CTRL vs. LOW and PLA (p = 0.004), and at recovery CTRL was higher than LOW (p = 0.015). Furthermore, an increase at post-exercise vs. resting values were shown in all study visits for: "WBC count and LYM%, while GRA%, RBC count and HGB concentration were decreased. Post-exercise MON% was greater vs. resting and recovery values in LOW (p < 0.001) and PLA (p = 0.001). PLT count was higher for all doses of NaHCO<sub>3</sub> (LOW, p = 0.001; *MED*, p < 0.001; *HIGH*, p = 0.002) at post-exercise in comparison to resting and recovery values, and PLA post-exercise vs. rest (p = 0.001).

Comparison between resting and recovery values showed differences for all study visits only for LYM%, GRA% and HGB concentration. WBC count had higher recovery values in *CTRL* (p < 0.001) and *PLA* (p < 0.001), but not any NaHCO<sub>3</sub> visit. For MON%,

decreased values at recovery vs. rest were shown only in *CTRL* (p < 0.001), and for RBC count in *MED* (p < 0.001) and *HIGH* (p < 0.001).

WBC count and LYM% were decreased (p < 0.001) at recovery vs. post-exercise in all visits, while there was an increased %GRA, RBC count and haemoglobin concentration (p < 0.001). Additionally, MON% was lower at recovery vs. post-exercise in *CTRL*, *LOW* and *PLA*, as was PLT count in *LOW*, *MED* and *HIGH*.

## Blood Biochemical Markers

All biochemical results are presented in Table 3.

There were significant differences between visits only for magnesium and creatinine concentration at recovery. Blood magnesium concentration was higher in *CTRL* vs. *HIGH* (p = 0.034), while creatinine concentration was lower in *CTRL* vs. *LOW* and *PLA* (p = 0.003).

There was an increase at post-exercise vs. rest in all study visits for ALT, AST, CK, and LDH, and creatinine, while urea concentrations were decreased. There were no significant differences for magnesium concentration.

Some of the exercise-induced biochemical markers returned to their resting values after a short period of recovery (except magnesium and creatinine concentrations, and ALT and CK activities). Moreover, in comparison to resting values, lower urea concentration (p < 0.001) was observed only in *LOW*, while higher AST occurred in *HIGH* (p < 0.001) and *CTRL* (p < 0.001). LDH was higher at recovery than at rest in *HIGH* (p = 0.003).

Urea and magnesium concentration were increased (all p < 0.001) at recovery vs. post-exercise in all visits. Additionally, lower ALT in *LOW* (p < 0.001), creatinine concentration in *CTRL* (p < 0.001) and LDH in *MED* (p < 0.001) were shown.

#### DISCUSSION

To our knowledge, this study is the first to assess different NaH- $CO_3$  dose supplementation-induced changes for haematological and biochemical indicators at rest, immediately after high-intensity exercises and after a 45-min recovery period. Undertaking such research could be extremely important to broaden the definition of the effect of this ergogenic agent to human (athlete) metabolism.

Resting values of pH and all haematological and biochemical blood indices did not differ across the five study visits (*CTRL*, *NaH-CO*<sub>3</sub>'s, *PLA*), which proves the homogeneity of the group for the studied indicators. This is an important aspect of research in order to properly compare the studied variables.

Post-exercise changes in blood pH values after taking different NaHCO<sub>3</sub> doses compared to *CTRL* and *PLA*, were improved and consistent with those reported so far in the literature [27, 28, 30, 35]. The higher the NaHCO<sub>3</sub> dose, the lower the post-workout acidification of the organism and more effective recovery of the index values back to resting values. Such an improvement in regeneration, acid-base balance indicators, when using NaHCO<sub>3</sub> before exercise was also presented in the work by Siegler et al. [35] and Mündel [37]. On the other hand, taking NaHCO<sub>3</sub> after exercise did not accelerate acid-base balance recovery, as indicated by Gurton et al. [38]. Thus, it seems clear that the ingestion of NaHCO<sub>3</sub> has to be performed before efforts and preferably according to specific absorption time [16].

Interestingly, post-exercise WBC counts returned to baseline values faster with all NaHCO<sub>3</sub> doses than with CTRL or PLA. However, these results did not have a direct impact on individual leukocyte subpopulations. The percentage values of LYM and GRA, despite differences between the CTRL phase and the remaining visits of study, do not indicate any effect of NaHCO<sub>3</sub> intake. In contrast, MON% remained stable throughout the study period with MED and HIGH NaHCO<sub>3</sub> supplementation doses. Such differences might be explained by the fact that the WBC count increases to counter exercise-induced inflammation [39]. Moreover, acidification of the body contributes to such an increase in inflammation [40]. Thus, if athletes supplement alkaline agents before exercise (e.g. with NaHCO<sub>3</sub>), inflammation may not be aggravated by acidosis and blood leukocytes count will be able to return to the resting state faster. Furthermore, extracellular buffering support may also hamper low blood pH-induced increase of the concentration of magnesium (Mg), due to the release of magnesium ions from complexes with proteins (mainly albumin), which, while buffering the blood, replace Mg with hydrogen  $(H^+)$  ions [41].

No effect of NaHCO<sub>3</sub> supplementation was noted for the HGB concentration and PLT count. Nevertheless, a relationship between NaHCO<sub>3</sub> *MED* or *HIGH* dose supplementation and the lower RBC count between recovery vs. resting values was found. This is a surprising result as reducing the acidity of the organism should reduce the risk of osmotic fragility of erythrocytes [42] and thus more RBC with increased buffering capacity would be expected. However, the mechanism of this phenomenon (a decreased of RBC count after NaHCO<sub>3</sub> supplementation or metabolic alkalosis) is unknown and

according to our literature review no research has been carried out in this respect.

Physical effort, especially of a high intensity nature, leads to substantial changes in the activity of intramuscular enzymes, especially CK and LDH [43]. The elevated level of these indicators persists for a long time after finishing intensive exercise and their return to reference values may last even several days [44]. Alkalizing factors, i.e. NaHCO<sub>3</sub>, should hypothetically protect muscles against increased damage by hydrogen ions generated during intense exercise. It should be noted that physical efforts also lead to an increase in body temperature, which can additionally damage cells. Interestingly, studies on cell cultures indicate that the presence of NaHCO<sub>3</sub> combining with vitamin C protects them from heat damage by increasing their antioxidant capacity [45]. In addition, studies in horses show that the administration of  $NaHCO_3$  reduces the symptoms of rhabdomyolysis [46]. After adding this supplement to the diet, the activity of muscle enzymes such as CK and AST were significantly reduced [46]. Similar results should be expected in athletes, although we did not show this in the current study as there was no relationship between the dose of NaHCO<sub>3</sub> and their protective role against muscle fibers. However, it should be underlined that no studies have been conducted in this aspect. In addition, our investigation indicated that NaH-CO<sub>3</sub> does not affect the urea concentration in blood which confirm similar observations in animal (rats) in vivo studies [47].

It could also be assumed that highly-trained athletes may have a strengthened buffering capacity potential, while less trained athletes seems to be more dependent on additional NaHCO<sub>3</sub> supplementation [48]. In our work, studied participants had substantial training experience (at least 4 years of training experience), so the lack of changes of muscle metabolites and enzymes activity may be the result of their adaptation to HIFT effort.

The strength of the described research is related primarily to the multi-crossover research design and novelty of supplementation of various FFM-adjusted doses in each participant. Much attention was also paid to compliance and control of the protocol, and use of recommended research methods allowing for biochemical monitoring and induction of innovatory divided high-intensity exercises procedure. It is important that the haematological and biochemical indicators determined constitute a kind of novelty in this matter. In addition, they were attended by people who train CrossFit on a daily basis, so the efforts established in the test protocol were familiar to them. It is also important to note that the participants of the research were highly involved in it and received feedback at the end, which increased their compliance and awareness of supplementation with NaHCO<sub>3</sub>.

Interestingly, it could be suggested that the observed similarities in analyzed results could be linked to the equimolar amount of sodium in  $NaHCO_3$  and *PLA* which should be confirmed in further studies.

Finally, the presented study brings a lot of new and important scientific and practical approaches. It seems important to monitor the influence of bicarbonate not only on acid-base balance, but also on other blood measures (haematological and biochemical).

#### CONCLUSIONS

The present study confirms the positive and dose-dependent alkalizing effect of NaHCO<sub>3</sub> after exercise and during a short term recovery period which may be desirable in terms of effective sport practice. The use of NaHCO<sub>3</sub> supplementation has a similar effect on haematological markers as a placebo apart from MON%, or WBC count, where a beneficial effect of supplementation on the faster return of the above-mentioned indicators to resting values was observed. Nevertheless, supplementation with NaHCO<sub>3</sub> did not affect the postexercise and recovery efficiency changes of the blood biochemical indicators in any way. The role of sodium intake in this process warrants further studies.

# Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Funding

This study was partially funded by the National Science Centre, Poland. K.D.-M has received research grant from the Polish National Science Centre (grant number 2018/02/X/NZ7/03217). Furthermore, K.D.-M. has participated in the Exchange Programme for Scientists as part of bilateral cooperation financed by The Polish National Agency for Academic Exchange (NAWA: BPN/ BIL/2021/1/00108/U/00001). B.S. (2016/50438-0 & 2021/06836-0) acknowledges a personal research grant from Fundação de Amparo à Pesquisa do Estado de São Paulo. B.S. also receives a grant from Faculdade de Medicina da Universidade de São Paulo (2020.1.362.5.2).

#### **REFERENCES**

- Robergs RA, Ghiasvand F, Parker D. Biochemistry of exercise-induced metabolic acidosis. Am J Physiol Regul Integr Comp Physiol. 2004; 287(3):R502–16.
- Gledhill N. Bicarbonate ingestion and anaerobic performance. Sports Med. 1984; 1(3):177–80.
- Bauer P, Zeissler S, Walscheid R, Frech T, Hillebrecht A. Acute effects of highintensity exercise on hematological and iron metabolic parameters in elite male and female dragon boating athletes. Phys Sportsmed. 2018; 46(3):335–341.
- Ohlsson L, Hall A, Lindahl H, Danielsson R, Gustafsson A, Lavant E, Ljunggren L. Increased level of circulating cell-free mitochondrial DNA due to a single bout of strenuous physical exercise. Eur J Appl Physiol. 2020; 120(4):897–905.
- Szanto S, Mody T, Gyurcsik Z, Babjak LB, Somogyi V, Barath B, Varga A, Matrai AA, Nemeth N. Alterations of Selected Hemorheological and Metabolic Parameters Induced by Physical Activity in Untrained Men and Sportsmen. Metabolites. 2021; 14; 11(12):870.

- Jamurtas AZ, Fatouros IG, Deli CK, Georgakouli K, Poulios A, Draganidis D, Papanikolaou K, Tsimeas P, Chatzinikolaou A, Avloniti A, Tsiokanos A, Koutedakis Y. The Effects of Acute Low-Volume HIIT and Aerobic Exercise on Leukocyte Count and Redox Status. J Sports Sci Med. 2018; 14; 17(3):501–508.
- Cordova A. Changes on plasmatic and erythrocytic magnesium levels after high-intensity exercises in men. Physiol Behav. 1992; 52(4):819–21.
- Skarpańska-Stejnborn A, Basta P, Trzeciak J, Szcześniak-Pilaczyńska Ł. Effect of intense physical exercise on hepcidin levels and selected parameters of iron metabolism in rowing athletes. Eur J Appl Physiol. 2015; 115(2):345–51.
- Bartolomei S, Sadres E, Church DD, Arroyo E, Gordon JA III, Varanoske AN, Wang R, Beyer KS, Oliveira LP, Stout JR, Hoffman JR. Comparison of the recovery response from high-intensity and high-volume resistance exercise in trained men. Eur J Appl Physiol. 2017; 117(7):1287–1298.

# **Conflict of interest**

I.Ł. is a shareholder of an alkali products distributor and has received honoraria from the Sanum Polska sp. z o. o. However, the content of this study was not constrained by this fact in absolutely no extend. K.D.-M., J.K., B.S., A.P., M.S., and T.P. report no conflicts of interest. The authors declare that the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.

# **Author Contributions**

Study design/planning: K.D.-M.; data collection/entry: K.D.-M., J.K., T.P; data analysis/statistics: K.D.-M, J.K.; data interpretation: K.D.-M., J.K., T.P; preparation of manuscript: K.D.-M, J.K., B.S., A.P., M.S., T.P; literature analysis/search: K.D.-M., J.K.; collection of funds: K.D.-M.

## Ethics approval

The study protocol was reviewed and approved by the local institutional review board (Bioethics Committee at Poznan University of Medical Sciences, reference number: 1000/18 of 11 October 2018) and registered at *ClinicalTrials.gov* (NCT03810404). All procedures were conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki.

# Patients' consent

Written informed consent was obtained from all participants before their participation in the study began.

- Kılıc Y, Cetin HN, Sumlu E, Pektas MB, Koca HB, Akar F. Effects of Boxing Matches on Metabolic, Hormonal, and Inflammatory Parameters in Male Elite Boxers. Medicina (Kaunas). 2019; 18; 55(6):288.
- Kartaram S, Mensink M, Teunis M, Schoen E, Witte G, Janssen Duijghuijsen L, Verschuren M, Mohrmann K, M'Rabet L, Knipping K, Wittink H, van Helvoort A, Garssen J, Witkamp R, Pieters R, van Norren K. Plasma citrulline concentration, a marker for intestinal functionality, reflects exercise intensity in healthy young men. Clin Nutr. 2019; 38(5):2251–2258.
- Medbø JI, Hanem S, Noddeland H, Jebens E. Arterio-venous differences of blood acid-base status and plasma sodium caused by intense bicycling. Acta Physiol Scand. 2000; 168(2):311–26.
- Lippi G, Sanchis-Gomar F. Epidemiological, biological and clinical update on exercise-induced hemolysis. Ann Transl Med. 2019; 7(12):270.
- 14. Wang XH, Mitch WE. Muscle wasting from kidney failure-a model for catabolic

## Sodium bicarbonate, exercise-induced fatigue and recovery

conditions. Int J Biochem Cell Biol. 2013; 45(10):2230–8.

- Durkalec-Michalski K, Zawieja EE, Podgórski T, Łoniewski I, Zawieja BE, Warzybok M, Jeszka J. The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial. PLoS One. 2018; 17; 13(5):e0197480.
- de Oliveira LF, Dolan E, Swinton PA, Durkalec-Michalski K, Artioli GG, McNaughton LR, Saunders B. Extracellular Buffering Supplements to Improve Exercise Capacity and Performance: A Comprehensive Systematic Review and Meta-analysis. Sports Med. 2022; 52(3):505–526.
- Freis T, Hecksteden A, Such U, Meyer T. Effect of sodium bicarbonate on prolonged running performance: A randomized, double-blind, cross-over study. PLoS One. 2017; 10; 12(8):e0182158.
- McNaughton LR, Siegler J, Midgley A. Ergogenic effects of sodium bicarbonate. Curr Sports Med Rep. 2008; 7(4):230–6.
- Isoardi KZ, Chiew AL. Too much of a good thing: Bicarbonate toxicity following treatment of sodium channel blocker overdose. Emerg Med Australas. 2022; 34(4):639–41.
- Grgic J, Pedisic Z, Saunders B, Artioli GG, Schoenfeld BJ, McKenna MJ, Bishop DJ, Kreider RB, Stout JR, Kalman DS, Arent SM, VanDusseldorp TA, Lopez HL, Ziegenfuss TN, Burke LM, Antonio J, Campbell BI. International Society of Sports Nutrition position stand: sodium bicarbonate and exercise performance. J Int Soc Sports Nutr. 2021; 9; 18(1):61.
- Siegler JC, Marshall PW, Bray J, Towlson C. Sodium bicarbonate supplementation and ingestion timing: does it matter? J Strength Cond Res. 2012; 26(7):1953–8.
- 22. Higgins MF, James RS, Price MJ. The effects of sodium bicarbonate (NaHCO3) ingestion on high intensity cycling capacity. J Sports Sci. 2013; 31(9):972–81.
- Saunders B, Sale C, Harris RC, Sunderland C. Sodium bicarbonate and high-intensity-cycling capacity: variability in responses. Int J Sports Physiol Perform. 2014; 9(4):627–32.
- 24. Ragone L, Guilherme Vieira J, Camaroti Laterza M, Leitão L, da Silva Novaes J, Macedo Vianna J, Ricardo Dias M. Acute Effect of Sodium Bicarbonate Supplementation on Symptoms of Gastrointestinal Discomfort, Acid-Base Balance, and Performance of Jiu-Jitsu Athletes. J Hum Kinet. 2020; 31; 75:85–93.

- Burke LM, Pyne DB. Bicarbonate loading to enhance training and competitive performance. Int J Sports Physiol Perform. 2007; 2(1):93–7.
- 26. Gurton WH, Gough LA, Sparks SA, Faghy MA, Reed KE. Sodium Bicarbonate Ingestion Improves Time-to-Exhaustion Cycling Performance and Alters Estimated Energy System Contribution: A Dose-Response Investigation. Front Nutr. 2020; 8; 7:154.
- 27. Cameron SL, McLay-Cooke RT, Brown RC, Gray AR, Fairbairn KA. Increased blood pH but not performance with sodium bicarbonate supplementation in elite rugby union players. Int J Sport Nutr Exerc Metab. 2010; 20(4):307–21.
- 28. AbuMoh'd MF, Alsababha W, Haddad Y, Obeidat G, Telfah Y. Effect of acute sodium bicarbonate intake on sprintintermittent performance and blood biochemical responses in well-trained sprinters. Monten J Sports Sci Med. 2021; 10(1):5.
- 29. Kerksick CM, Wilborn CD, Roberts MD, Smith-Ryan A, Kleiner SM, Jäger R, Collins R, Cooke M, Davis JN, Galvan E, Greenwood M, Lowery LM, Wildman R, Antonio J, Kreider RB. ISSN exercise & sports nutrition review update: research & recommendations. J Int Soc Sports Nutr. 2018; 15(1):38.
- 30. Carr AJ, Slater GJ, Gore CJ, Dawson B, Burke LM. Effect of sodium bicarbonate on [HCO<sub>3</sub><sup>-</sup>], pH, and gastrointestinal symptoms. Int J Sport Nutr Exerc Metab. 2011; 21(3):189–94.
- 31. Durkalec-Michalski K, Nowaczyk PM, Adrian J, Kamińska J, Podgórski T. The influence of progressive-chronic and acute sodium bicarbonate supplementation on anaerobic power and specific performance in team sports: a randomized, double-blind, placebocontrolled crossover study. Nutr Metab (Lond). 2020; 24; 17:38.
- 32. Durkalec-Michalski K, Zawieja EE, Zawieja BE, Podgórski T. Evaluation of the repeatability and reliability of the cross-training specific Fight Gone Bad workout and its relation to aerobic fitness. Sci Rep. 2021; 31; 11(1):7263.
- Podgórski T, Bartkowiak U, Pawlak M. Comparison of hematological parameters of venous and capillary blood in athletes. Trends Sport Sci. 2014; 21(1).
- 34. Durkalec-Michalski K, Nowaczyk PM, Główka N, Ziobrowska A, Podgórski T. Is a Four-Week Ketogenic Diet an Effective Nutritional Strategy in CrossFit-Trained Female and Male Athletes? Nutrients. 2021; 6; 13(3):864.
- 35. Gough LA, Deb SK, Brown D, Sparks SA, McNaughton LR. The effects of sodium bicarbonate ingestion on cycling performance and acid base balance

recovery in acute normobaric hypoxia. J Sports Sci. 2019; 37(13):1464–1471.

- 36. Siegler JC, Keatley S, Midgley AW, Nevill AM, McNaughton LR. Pre-exercise alkalosis and acid-base recovery. Int J Sports Med. 2008; 29(7):545–51.
- Mündel T. Sodium bicarbonate ingestion improves repeated high-intensity cycling performance in the heat. Temperature (Austin). 2018; 13; 5(4):343–347.
- 38. Gurton W, Macrae H, Gough L, King DG. Effects of post-exercise sodium bicarbonate ingestion on acid-base balance recovery and time-to-exhaustion running performance: a randomised crossover trial in recreational athletes. Appl Physiol Nutr Metab. 2021; 46(9):1111–1118.
- Edwards KM, Burns VE, Carroll D, Drayson M, Ring C. The acute stress-induced immunoenhancement hypothesis. Exerc Sport Sci Rev. 2007; 35(3):150–5.
- 40. Okajima F. Regulation of inflammation by extracellular acidification and protonsensing GPCRs. Cell Signal. 2013; 25(11):2263–71.
- 41. Wang S, McDonnell EH, Sedor FA, Toffaletti JG. pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med. 2002; 126(8):947–50.
- 42. Reinhart WH, Gaudenz R, Walter R. Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity. J Crit Care. 2002; 17(1):68–73.
- Brancaccio P, Maffulli N, Buonauro R, Limongelli FM. Serum enzyme monitoring in sports medicine. Clin Sports Med. 2008; 27(1):1–18.
- 44. Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkström V, Ekelund M. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008; 65(2):253–9.
- 45. Yin B, Tang S, Sun J, Zhang X, Xu J, Di L, Li Z, Hu Y, Bao E. Vitamin C and sodium bicarbonate enhance the antioxidant ability of H9C2 cells and induce HSPs to relieve heat stress. Cell Stress Chaperones. 2018; 23(4):735–748.
- Robb EJ, Kronfeld DS. Dietary sodium bicarbonate as a treatment for exertional rhabdomyolysis in a horse. J Am Vet Med Assoc. 1986; 15; 188(6):602–7.
- 47. Halperin ML, Chen CB, Cheema-Dhadli S, West ML, Jungas RL. Is urea formation regulated primarily by acid-base balance in vivo? Am J Physiol. 1986; 250(4 Pt 2):F605–12.
- Peart DJ, Siegler JC, Vince RV. Practical recommendations for coaches and athletes: a meta-analysis of sodium bicarbonate use for athletic performance. J Strength Cond Res. 2012; 26(7):1975–83.